Vagus Nerve Stimulation (VNS)

Overview

What It Is Vagus nerve stimulation (VNS) uses electrical pulses to activate the vagus nerve, which carries signals between the body and brain and influences arousal, inflammation, mood, and seizure networks. VNS is delivered in several forms: fully implanted systems, non-invasive external devices (ear or neck), and specialized approaches that pair stimulation with rehabilitation. The goal is to modulate brain and autonomic activity in ways that can reduce seizures, support mood, enhance motor recovery, or influence other neurological symptoms.

How It Works Stimulating vagal pathways affects brainstem nuclei that gate cortical excitability, autonomic state, and limbic activity. Repeated or carefully timed stimulation can reduce seizure likelihood, support mood regulation, or—when paired with therapy—amplify use-dependent neuroplasticity so practice has a stronger effect on recovery. Different devices target the nerve in different places (neck implant, ear, tongue-related cranial nerve pathways) and with different timing strategies.

Main types and how they are delivered - Implanted VNS — A pulse generator is surgically placed under the skin (usually chest) with a lead on the left vagus nerve in the neck. The device delivers regular or responsive pulses and is programmed over time. Established for drug-resistant epilepsy; also used for treatment-resistant depression in approved settings. - Paired VNS for motor recovery (e.g., Vivistim) — An implanted vagus stimulator is timed to fire during specific rehabilitation movements. Stimulation is paired with high-quality physical or occupational therapy so each practice trial is reinforced by neuromodulation. FDA-approved for upper-limb recovery after chronic ischemic stroke when used with rehab. - Transcutaneous / external VNS (including taVNS) — Non-invasive ear or neck electrodes deliver mild pulses at home or in clinic on a set schedule. Used or studied for mood, seizure adjunct, pain, inflammation, and other targets. No surgery; mainly local skin effects. - Tongue-based / cranial-nerve neuromodulation related to VNS pathways (e.g., PoNS) — A mouthpiece delivers stimulation to the tongue while the user performs physical-therapy exercises. Used for gait and balance deficits (e.g., in MS or chronic stroke) under supervised protocols. Related by cranial-nerve neuromodulation and pairing with therapy rather than classic cervical VNS. - Wearable and emerging external systems — Consumer and clinical wearables continue to expand non-invasive options for scheduled or on-demand stimulation.

Pairing with other therapies Many modern VNS approaches are designed to be combined with active rehabilitation. Paired VNS (Vivistim) and PoNS protocols explicitly couple stimulation with physical or occupational therapy so the brain is more plastic during practice. Implanted and taVNS programs are also often used alongside medication, counseling, or standard neurorehab rather than as stand-alone cures.

Example devices, technologies, and programs - Implanted VNS systems (e.g., LivaNova and related epilepsy/depression platforms) - Vivistim — paired VNS for chronic stroke upper-limb recovery with rehab - PoNS (Portable Neuromodulation Stimulator) — tongue stimulation paired with PT for gait/balance - taVNS / transcutaneous auricular VNS devices — ear-electrode systems for non-invasive use - Other external cervical or wearable VNS devices under clinical or consumer pathways

On-label / regulatory status - Implanted VNS: FDA-approved for drug-resistant epilepsy; also approved in specific contexts for treatment-resistant depression. - Paired VNS (Vivistim): FDA-approved for upper-limb motor recovery after chronic ischemic stroke when used with rehabilitation. - PoNS: FDA-cleared for gait deficit in mild-to-moderate MS and for chronic stroke gait impairment when used with physical therapy. - taVNS / many wearables: generally cleared or marketed for narrower wellness or specific indications; broader mood, pain, and epilepsy-adjunct uses are often off-label or investigational depending on the device and claim.

Conditions - Strongest established use: drug-resistant epilepsy (implanted VNS) - Also approved or cleared in specific forms for: treatment-resistant depression (selected implanted systems); upper-limb motor recovery after chronic stroke (paired VNS with therapy); gait deficit in MS or chronic stroke (PoNS with PT) - Emerging / researched: mood, pain, inflammation, cognitive symptoms, and other neurological applications with non-invasive devices

How it is administered

Depends on type: surgical implant plus ongoing programming (implanted and paired VNS); at-home or clinic ear/neck electrode sessions (taVNS); supervised clinic and home use of a tongue mouthpiece with physical therapy (PoNS). Paired approaches require concurrent rehab. Wearables follow manufacturer and clinician schedules.

The NPA Treatment Database lists this treatment in connection with 8 condition records. A database relationship does not establish effectiveness, safety, or suitability for an individual.

These controlled question pages reference this treatment through stored condition relationships.

Symptoms connected in the NPA database

The current record associates this treatment with the following symptom information. This is not a claim that the treatment will improve these symptoms.

Cognition & Memory

concentration issues
Confusion or memory gaps after seizures
difficulty concentrating
Difficulty concentrating (“brain fog”)
indecisiveness
Later memory and thinking changes
memory
memory complaints
mental fog
multitasking difficulty
Problems with concentration
racing thoughts
Short-term memory issues
Short-term memory problems
slowed mental processing
slowed processing
slowed thinking
spatial neglect
worry

Emotion & Behavior

anxiety
anxiety around seizures
apathy
avoidance behaviors
Depression
emotional control issues
emotional lability (uncontrollable laughing/crying)
Excessive fear or worry
Fear or déjà vu auras
feelings of worthlessness
frustration
impulsivity
irritability
loss of interest/pleasure
mood changes
mood swings
Persistent sadness
social withdrawal

Motor Control

Balance and coordination problems
balance and gait problems
difficulty walking
guarding
loss of muscle control
muscle stiffness/spasticity
muscle tension
Muscle weakness
One-sided weakness or paralysis
poor balance and coordination
post-seizure weakness
reduced fine motor skills
Reduced mobility
Restlessness
rigidity/stiffness
Seizure-related jerking
slowed movement (bradykinesia)
slowed movements
Slowed movements or restlessness (psychomotor changes)
stiffening
stiffness/spasms
trembling
Tremor
walking difficulty
weakness

Sensory & Pain

central post-stroke pain (burning, shooting pain, and sensitivity to touch, temperature)
electric-shock sensations
headaches
heightened sensitivity
muscle aches
Numbness or altered sensation
numbness or tingling
pain
Persistent headaches
Persistent pain (aching, burning, stabbing)
Physical sensations (heart racing, chest tightness, sweating)
reduced sense of smell
sensitivity to light/noise
Sensory auras (tingling, unusual sensations)
sensory changes
tinnitus
Unexplained aches and pains

Sleep & Fatigue

Excessive fatigue
Extreme fatigue (one of the most common symptoms)
fatigue
Insomnia or excessive sleepiness
Insomnia or hypersomnia
Post-ictal fatigue
profound fatigue and low energy
profound physical and mental fatigue
Sleep disruption due to pain
sleep disruption from nocturnal seizures
sleep disturbances
Sleep problems (including REM sleep behavior disorder)
Trouble falling or staying asleep

Practical information

Insurance coverage

Implanted VNS is often covered for eligible drug-resistant epilepsy (and sometimes depression) when criteria are met. Paired VNS and PoNS coverage varies by indication and plan. Non-invasive taVNS and consumer devices are frequently out-of-pocket.

Cost information

Implanted and paired systems: high (device + surgery + therapy). PoNS: substantial device-plus-therapy cost. Non-invasive taVNS/wearables: typically hundreds to low thousands of dollars.

Results and outcomes described in the source record

Implanted VNS: benefits often build over months to years. Paired VNS and PoNS: assessed over weeks of combined stimulation and therapy. Non-invasive taVNS: often evaluated over weeks of regular use.

Side effects and risks

Implanted: surgical risks; common side effects include voice changes, cough, throat sensation. Paired VNS: similar implant-related effects. PoNS: tongue/mouth irritation. taVNS/wearables: mainly local skin irritation. Medical screening is required for invasive forms.

Research context in the NPA database

This section reproduces the current database's research summary and detail. Structured citation metadata has not been supplied, so it should not be read as an independently verified literature review.

Research summary

Evidence Level: Strong (implanted VNS for epilepsy); Moderate to Strong (paired VNS for chronic stroke arm recovery; PoNS for selected gait indications); Emerging to Moderate (non-invasive taVNS for mood and other uses) What the research shows: Decades of data support implanted VNS for seizure reduction. Paired VNS and PoNS trials support adding stimulation to rehab for motor outcomes. Non-invasive forms have growing but more variable evidence. Key takeaway: A family of approaches—from implanted to wearable—that modulate vagal/cranial-nerve pathways; strongest results when the right device is matched to the indication and, when relevant, paired with active therapy.

Research detail

Overview Vagus nerve stimulation includes implanted, paired, tongue-based, and non-invasive forms that electrically activate vagal or related cranial-nerve pathways to influence brain and autonomic networks. Many modern protocols intentionally pair stimulation with rehabilitation.

Evidence Base and Published Work • Implanted VNS: strong long-term evidence for reducing seizure frequency in drug-resistant epilepsy; also used for treatment-resistant depression in approved contexts. • Paired VNS (Vivistim): pivotal trial support for improved upper-limb outcomes after chronic ischemic stroke when stimulation is paired with therapy. • PoNS: clinical studies and clearances for gait improvement in MS and chronic stroke when used with physical therapy. • taVNS and other non-invasive systems: expanding research in mood, seizures, pain, and inflammation; evidence quality varies by indication. • Across forms, pairing stimulation with skilled practice is a recurring strategy to enhance neuroplasticity.

Outcomes Outcomes most frequently described include fewer seizures (implanted VNS), better arm function when paired with rehab (Vivistim), improved gait/balance with PT (PoNS), and emerging symptom benefits with non-invasive devices. Results depend on device type, indication, and concurrent therapy.

Questions to ask a provider

1. Which form of VNS is appropriate for my condition—implanted, paired with rehab (e.g., Vivistim), PoNS with PT, or non-invasive taVNS/wearable? 2. Is the recommended approach FDA-approved or cleared for my indication, or is it off-label/investigational? 3. How is stimulation timed or paired with physical, occupational, or other therapy? 4. What side effects and surgical vs non-surgical risks should I understand? 5. What is the total cost, what will insurance cover, and which centers or programs deliver this type of VNS?

Website and contact information

Visit the related website

Explore the interactive Treatment Database

Continue to compare educational treatment information in the interactive database. The standard disclaimer acknowledgement is required before the database opens.

Explore treatment information in the database